Professional Health Print Ad Spend Through September 2016
Advertising spend in professional health print journals totalled $471 million from January-September 2016 according to Kantar Media’s Healthcare data.
Lilly has been spending big in 2016, holding onto the top spot since March of this year. Novartis made its way back into the top five spenders after being knocked out by Amgen in August.
While other drugs have been pulling back on advertising in print journals, Harvoni Tablets has been the only drug in the top five increasing spend compared to 2015. Gilead has been investing heavily in advertising for the drug. Indeed, Harvoni Tablets account for 69 percent of the drug maker’s professional health print journal spend for the year thus far.
A total of 73,734 ad pages have been purchased in professional health print journals from January-September 2016. The top drug class advertising by both dollars and pages is Cancer Therapy (Antineoplastic Agents).
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in professional healthcare. This analysis is part of ongoing healthcare reporting we release on a monthly basis. Make sure to check back next month for the most recent data, or contact us to learn more!